Applied physicists in the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) have discovered a new way ...

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic ...

Vera Therapeutics Inc. (NASDAQ:VERA) is one of the 13 hot stocks to buy with the highest upside potential. As of February 13, ...

A live webcast will be accessible through the Company’s website at www.verupharma.com. Following the event, an archived webcast will be available on the Veru website.

The laser module is one of the least reliable components in such a system. For that reason, it remains in a convenient ...

Japan Patent Office issues a notice of allowance to Moleculin Biotech for patent application covering annamycin: Houston Thursday, February 19, 2026, 16:00 Hrs [IST] Moleculin Bio ...

Princeton, New Jersey Thursday, February 19, 2026, 11:00 Hrs [IST] ...

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.

Getting the right vitamins and minerals through diet or supplementation can help support bone strength, heart health, energy levels, and healthy aging.

Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announced that ...

Resistant cells demonstrated global decreases in DNA accessibility with localized opening at resistance-driving loci, indicating non-mutational epigenetic reprogramming rather than canonical oncogenic ...

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.